<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01885598</url>
  </required_header>
  <id_info>
    <org_study_id>CV185-259</org_study_id>
    <nct_id>NCT01885598</nct_id>
  </id_info>
  <brief_title>Eliquis Regulatory Post Marketing Surveillance</brief_title>
  <official_title>Eliquis (Apixaban) Regulatory Postmarketing Surveillance in Clinical Practice for Stroke Prevention in Nonvalvular Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to examine the safety profile of Eliquis in Korean
      nonvalvular atrial fibrillation patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 10, 2013</start_date>
  <completion_date type="Actual">September 29, 2017</completion_date>
  <primary_completion_date type="Actual">September 29, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events (AE) occurrence based on Incidence of serious adverse events, unexpected adverse drug reactions, Identification of AE profile in usual practice Nonserious adverse events, major bleeding</measure>
    <time_frame>within 30 days after end of the treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Final identification of major events and no event based on Incidence of stroke, systemic embolism, death, Effectiveness or death at 24 months after discontinuation of therapy or at the end of the observation period (whatever is later)</measure>
    <time_frame>At 3, 6, 12, and 24 months after enrollment</time_frame>
    <description>Final identification of major events based on Incidence of stroke, systemic embolism, death, Effectiveness: No evidence of stroke, systemic embolism, or death at 24 months after discontinuation of therapy or at the end of the observation period (whatever is later)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Final evaluation of clinical significance of Eliquis is provided by the physician's subjective decision (Excellent, Good, Moderate, Insufficient)</measure>
    <time_frame>At 3, 6, 12, and 24 months after enrollment</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">3335</enrollment>
  <condition>NonValvular Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Nonvalvular Atrial Fibrillation patients with risk of Stroke</arm_group_label>
    <description>Patients undergoing elective total hip replacement arthroplasty or elective total knee replacement arthroplasty and signed on the data release</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apixaban</intervention_name>
    <arm_group_label>Nonvalvular Atrial Fibrillation patients with risk of Stroke</arm_group_label>
    <other_name>Eliquis</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients visiting outpatient department of hospital
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com

        Inclusion Criteria:

          -  Patients â‰¥19 years of age

          -  Adult patients who are diagnosed with nonvalvular atrial fibrillation and are
             initiating Eliquis anticoagulation therapy for risk reduction of stroke and systemic
             embolism

          -  Patients with evidence of a personally signed and dated informed consent document
             indicating that the patient (or a legally acceptable representative) has been informed
             of all pertinent aspects of the study

        Exclusion Criteria:

          -  Receiving Eliquis treatment for an indication that is not approved in Korea

          -  Contraindicated for the use of Eliquis as described in the Korean label
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Seoul</city>
        <zip>110-756</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_inquiry_form.aspx</url>
    <description>Investigator Inquiry Form</description>
  </link>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 21, 2013</study_first_submitted>
  <study_first_submitted_qc>June 21, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 25, 2013</study_first_posted>
  <last_update_submitted>October 27, 2017</last_update_submitted>
  <last_update_submitted_qc>October 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apixaban</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

